A Radical Treatment for Insulin Pricing

A Radical Treatment for Insulin PricingA private, nonprofit company recently announced that it intends to bypass the traditional supply chain and sell interchangeable biosimilar insulin products at substantially reduced prices.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 386; no. 23; pp. 2157 - 2159
Main Author: Dafny, Leemore S.
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 09.06.2022
Subjects:
and the FDA
Biological products
Brand names
Cost control
Cost of Health Care
Devices
Diabetes
Drug stores
Drugs
Endocrinology
Generic drugs
Health Policy
Insulin
Patients
Pharmaceutical industry
Pharmacy
Prices
Profits
Rebates
Supply chains
United States > US
Health Policy
Medicine and Business
Drug and Device Safety
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A Radical Treatment for Insulin PricingA private, nonprofit company recently announced that it intends to bypass the traditional supply chain and sell interchangeable biosimilar insulin products at substantially reduced prices.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMp2203001